Octreotide Pregnancy and Breastfeeding Warnings
Octreotide Pregnancy Warnings
Octreotide has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetotoxicity or teratogenicity. There are no controlled data from human pregnancy. Octreotide should only be given during pregnancy when benefit outweighs risk.
Although acromegaly may lead to infertility, there are reports of pregnancy in acromegalic women. In women with active acromegaly who have been unable to become pregnant, normalization of growth hormone (GH) and insulin-like growth factor (IGF-1) may restore fertility. Female patients of childbearing potential should be advised to use adequate contraception during treatment with octreotide. There are no reports of adverse effects or teratogenicity associated with octreotide during human pregnancy. Preliminary data (based on six case reports) suggest that octreotide during could be safe and effective. Below are some details on four of those case reports. A 37-year-old woman with acromegaly and infertility became pregnant within 60 to 84 hours after the first injection of octreotide, which had been given in preparation for surgical excision of a pituitary adenoma. The pregnancy was discovered coincidentally during a routine preoperative ultrasound examination for suspected octreotide-induced gallstones. Once pregnancy was diagnosed, octreotide was discontinued. The pregnancy was only complicated by imminent foetal asphyxia at term, prompting Cesarean section delivery. The newborn, weighing 2,530 grams and measuring 46.0 cm in length, had no malformations and developed normally. A 36-year-old woman with acromegaly and amenorrhea secondary to pituitary macroadenoma became pregnant 14 months after starting octreotide therapy and 9 months after starting bromocriptine therapy. Once the pregnancy was diagnosed, all medications were discontinued. The pregnancy was complicated by impaired glucose tolerance and, near gestation week 40, signs of acute maternal intracranial hypertension and foetal distress. A newborn, weighing 3,540 grams and measuring 50 cm in length, was born by emergency Cesarean section. The infant required mechanical ventilation for three days, but showed no malformations, and developed normally. A 31-year-old woman with infertility secondary to pituitary macroadenoma became pregnant 4 months after starting octreotide therapy. One month after the pregnancy was diagnosed, octreotide therapy was discontinued. After withdrawal of octreotide therapy, serum TSH levels and thyroid hormone levels returned to elevated pretreatment values. At six months of pregnancy, a large pituitary macroadenoma with marked suprasellar extension was shown on MRI. Octreotide was restarted during the seventh month of pregnancy and was continued until time of delivery by Cesarean section. The newborn, weighing 3300 grams and measuring 51 cm in length, had no malformations and developed normally. Additionally, a successful pregnancy in a 36-year-old woman treated with octreotide during the second and third trimesters has also been reported.
Octreotide Breastfeeding Warnings
There are no data on the excretion of octreotide into human milk.
- Octreotide use while Breastfeeding (in more detail)
- octreotide Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.